December 27, 2012
Dr. Leon R. Kass, the Addie Clark Harding Professor Emeritus in the Committee on Social Thought and the College at the University of Chicago and former chairman of the President’s Council on Bioethics under former President George W. Bush, has written a report entitled “The Meaning of Life – In the Laboratory”.
Kass discusses the morality surrounding the US government’s funding of “research on human embryonic stem cells, cells derived from early embryos produced by in vitro fertilization in assisted-reproduction clinics.”
According to the report, the use of human embryos is justified by the advancements of science which demands that new policies be written to account for the development of regenerative medicine. Kass maintains that stem cells save lives, and therefore their use in research are necessary. Although he states that “we must also strive to protect and preserve human dignity”, Kass believes that with regard to abortions and stem cell research the continuation of this medical research is “worth preserving.”
Earlier this year, the Obama Administration has approved the use of aborted fetuses in the use of research, even though this practice was previously banned. Obama utilized a loophole in the legislation that abortion clinics are taking advantage of to sell the aborted fetus parts to corporations for scientific study. The loophole allows for “reasonable payments associated with the transportation, implantation, processing, preservation, quality control, or storage of human fetal tissue.” Medical researchers and abortion clinics have partnered quietly without the knowledge of the American public.
Whistleblower from LifeDynamics explains how this sneak around the legalities is achieved.
1. A baby parts “wholesaler” enters into a financial agreement with an abortion clinic in which the wholesaler pays a monthly “site fee” to the clinic. For this payment, the wholesaler is allowed to place a retrieval agent inside the clinic where he or she is given access to the corpses of children killed there and a workspace to harvest their parts. In most cases, this retrieval agent is an employee of the wholesaler. In other instances, the retrieval agent is a clinic employee who was trained by the wholesaler.
2. The buyer – usually a researcher working for a medical school, pharmaceutical company, bio-tech company or government agency – supplies the wholesaler with a list of the baby parts wanted.
3. When such orders are received by the wholesaler, they are faxed to the retrieval agent at the clinic who harvests the requested parts and ships them to the buyer via FedEx, Airborne or a similar common carrier.
4. These parts are “donated” by the clinic to the wholesaler who turns around and “donates” them to the buyer. The buyer then “reimburses” the wholesaler for the cost of retrieving the parts.
In 1999, The US House of Representatives approved HR 350 that gives Congress authority to inquire into private corporations who deal in trafficking of baby parts for profit.
PepsiCo was using Senomyx to obtain aborted human embryonic kidney tissue in a certain additive as a flavor chemical. PepsiCo had many other options rather than using this human concoction in their products, yet they continued on without the batting of an eye at the lack of concern for public health. Senomyx claims the human tissue is no more than “isolated human taste receptors”.
In a decision delivered Feb 28, 2012, President Obama and his Security and Exchange Commission (SEC) says this constitutes “ordinary business operations”. Attorney Brian Pitko, SEC Office of Chief Counsel, sent a letter to PepsiCo in response to a 36-page document submitted by PepsiCo attorneys in January, 2012. This move was a plea for SEC to ignore the claims of the shareholders of PepsiCo to protect their interests.
PepsiCo claimed that their shareholders could not make an informed judgment over this issue; essentially calling them idiots.
Debi Vinnedge, Executive Director of CGL, regarding the SEC decision, remarked: “We’re not talking about what kind of pencils PepsiCo wants to use — we are talking about exploiting the remains of an aborted child for profit. Using human embryonic kidney (HEK-293) to produce flavor enhancers for their beverages is a far cry from routine operations!”
PepsiCo claims the aborted human tissue is not included in the final product sold to customers. However, their flippant response to public health concerns causes a person capable of critical thinking to take that statement with a grain of salt. This corporation has no moral loyalty to its customers or shareholders. They care about the financial outcome. And after feeling the effects of a boycott, perhaps PepsiCo will change their view of ethical products and the right of the public to choose who they support.
The US government is the biggest distributor to research into “fetal tissue and cell lines”. The National Institutes of Health (NIH) have granted the Birth Defects Research Laboratory (BDRL) at the University of Washington $579,091 in 2011. The “products” were all derived from pregnant women possibly using non-surgical abortion methods to preserve the specimens capturing their integrity. The BDRL have also turned to local abortion clinics for a steady supply of fetuses for research.
One of Obama’s endeavors is to empower the genetic and biotech industry with the support of embryotic stem cell research. Genetic engineering has led researchers to discover over 4,500 diseases that need pharmaceutical drugs to combat.
The NIH will begin working with Pfizer Inc, AstraZeneca Plc and Eli Lilly and Co. in agreements to create compounds to be made available for trial use in a planned project.
“Americans are eagerly awaiting the next generation of cures and treatments to help them live longer and healthier lives,” Health and Human Services Secretary Kathleen Sebelius said in a statement. “To accelerate our nation’s therapeutic development process, it is essential that we forge strong, innovative, and strategic partnerships across government, academia, and industry.”
This alliance was further solidified after the US Senate gave their approval to the Food and Drug Administration (FDA), in conjunction with certain pharmaceutical corporations, for a $6.4 billion “agreement fee” in the new Food and Drug Administration Safety and Innovation Act, S. 3187 (FDASI).
The focus of this collaboration will identify new uses for drugs that have already been approved by FDA. There may be need for new human trials, putting the general public at a health risk. Engaging in experimental trials to classify specific compounds to be utilized for unintended purposes is highly dangerous.
Drug manufacturers and medical device makers are anxious to work with the US government. This will mean their treatments will be reviewed and approved faster than they currently are. The FDASI specifies that certain measures be taken to expedite the approval of medical treatments under the guise of “life-threatening” or rush monitoring devices to mitigate drug shortages.